Fortrea Holdings(NASDAQ) FTRE

Fortrea Holdings Inc. helps companies develop new medicines. They manage clinical trials to ensure new treatments are safe. The firm guides drugs from early testing to final approval.

Essential Clinical Solutions

• Clinical Services: Management of Phase I to IV clinical trials for drug developers across more than 20 therapeutic areas.
• Enabling Services: Technology and patient access solutions that simplify trial randomization and medication supply management.
• Clinical Pharmacology: Specialized support for early-stage study mix and net new business development.

Strategic Steps to Independence

• Completed a spin-off from Labcorp on June 30, 2023, to operate as an independent global entity.
• Sold the Enabling Services segment during the six-month period ended June 30, 2025.
• Amended its $300 million accounts receivable securitization program on Feb. 24, 2026, to extend the facility until 2029.

A Global Network for Research

Fortrea operates in approximately 100 countries and employs 14,000 people to support global drug development. It uses its proprietary Fortrea Intelligent Technology platform to deliver clinical data insights and streamline trial management.

Financial Results and Backlog

• Revenue was $678.2 million for the three months ended June 30, 2026, down 4.5% year over year.
• Backlog reached $7.8 billion as of June 30, 2026.
• Direct costs were 79.5% of revenue for the three months ended June 30, 2026, compared to 81.2% in the prior-year period.
• Selling, general, and administrative expenses decreased 18.2% to $102.1 million for the three months ended June 30, 2026.
• Cash and cash equivalents totaled $168.6 million as of June 30, 2026.

Bottom Line

Fortrea has successfully transitioned from a corporate division into a standalone clinical research specialist. It focuses on using its global scale and technological tools to improve the efficiency of biopharmaceutical development.